Infectopharm Arzneimittel GmbH
9
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
56%
5 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Fosfomycin I.v. for Treatment of Severely Infected Patients
Role: lead
Therapy for Scabies With Two Differently Concentrated Permethrin Creams
Role: lead
Comparative Head Lice Therapy With Dimet 5® vs. Hedrin® Once
Role: lead
5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis
Role: lead
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
Role: lead
Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
Role: lead
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
Role: lead
Treatment of Actinic Keratosis With 5% KOH Solution
Role: lead
Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection
Role: lead
All 9 trials loaded